Aegis Keeps Catalyst Pharm (CPRX) at Buy; New FDA Guidelines Won't Delay Firdapse
Tweet Send to a Friend
Aegis Capital maintains its Buy rating and $6 price target on Catalyst Pharmaceutical Partners Inc. (CPRX) following news earlier that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
